Haem is crucial for medium-dependent metronidazole resistance in clinical isolates of Clostridioides difficile

J Antimicrob Chemother. 2021 Jun 18;76(7):1731-1740. doi: 10.1093/jac/dkab097.

Abstract

Background: Until recently, metronidazole was the first-line treatment for Clostridioides difficile infection and it is still commonly used. Though resistance has been reported due to the plasmid pCD-METRO, this does not explain all cases.

Objectives: To identify factors that contribute to plasmid-independent metronidazole resistance of C. difficile.

Methods: Here, we investigate resistance to metronidazole in a collection of clinical isolates of C. difficile using a combination of antimicrobial susceptibility testing on different solid agar media and WGS of selected isolates.

Results: We find that nearly all isolates demonstrate a haem-dependent increase in the MIC of metronidazole, which in some cases leads to isolates qualifying as resistant (MIC >2 mg/L). Moreover, we find an SNP in the haem-responsive gene hsmA, which defines a metronidazole-resistant lineage of PCR ribotype 010/MLST ST15 isolates that also includes pCD-METRO-containing strains.

Conclusions: Our data demonstrate that haem is crucial for medium-dependent metronidazole resistance in C. difficile.

Publication types

  • Research Support, N.I.H., Intramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Clostridioides
  • Clostridioides difficile* / genetics
  • Clostridium Infections* / drug therapy
  • Heme
  • Humans
  • Metronidazole / pharmacology
  • Microbial Sensitivity Tests
  • Multilocus Sequence Typing
  • Ribotyping

Substances

  • Anti-Bacterial Agents
  • Metronidazole
  • Heme